4.8 Article

Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma

期刊

NATURE CHEMICAL BIOLOGY
卷 6, 期 2, 页码 133-139

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/NCHEMBIO.281

关键词

-

资金

  1. US National Institutes of Health [DK46335, CA58896, AI42266]
  2. Skaggs Institute for Chemical Biology
  3. Lita Annenberg Hazen Foundation
  4. US Department of Energy, Office of Basic Energy Sciences [W-31-109-Eng-38]

向作者/读者索取更多资源

A small molecule that could bind selectively to and then react chemoselectively with a non-enzyme protein in a complex biological fluid, such as blood, could have numerous practical applications. Herein, we report a family of designed stilbenes that selectively and covalently modify the prominent plasma protein transthyretin in preference to more than 4,000 other human plasma proteins. They react chemoselectively with only one of eight lysine epsilon-amino groups within transthyretin. The crystal structure confirms the expected binding orientation of the stilbene substructure and the anticipated conjugating amide bond. These covalent transthyretin kinetic stabilizers exhibit superior amyloid inhibition potency compared to their noncovalent counterparts, and they prevent cytotoxicity associated with amyloidogenesis. Though there are a few prodrugs that, upon metabolic activation, react with a cysteine residue inactivating a specific non-enzyme, we are unaware of designed small molecules that react with one lysine epsilon-amine within a specific non-enzyme protein in a complex biological fluid.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma

Luke T. Nelson, Ryan J. Paxman, Jin Xu, Bill Webb, Evan T. Powers, Jeffery W. Kelly

Summary: The research indicates that the drug candidates AG10, tolcapone, diflunisal, and tafamidis exhibit similar kinetic stabilization at specific concentrations, with differences in safety, absorption and metabolism, pharmacokinetics, and tissue distribution becoming important factors for clinical use decisions regarding kinetic stabilizers.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2021)

Letter Biochemistry & Molecular Biology

Untitled Response

Jeffery Kelly, Evan Powers

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2021)

Article Neurosciences

α-Synuclein Oligomers Induce Glutamate Release from Astrocytes and Excessive Extrasynaptic NMDAR Activity in Neurons, Thus Contributing to Synapse Loss

Dorit Trudler, Sara Sanz-Blasco, Yvonne S. Eisele, Swagata Ghatak, Karthik Bodhinathan, Mohd Waseem Akhtar, William P. Lynch, Juan C. Pina-Crespo, Maria Talantova, Jeffery W. Kelly, Stuart A. Lipton

Summary: In Parkinson's disease, synaptic and neuronal loss are prominent features. The study reveals that alpha Syn oligomers induce excessive glutamate release from astrocytes, activating NMDARs on neurons and leading to synaptic damage. However, the drug NitroSynapsin shows promise in protecting synapses from alpha Syn-induced damage.

JOURNAL OF NEUROSCIENCE (2021)

Article Cell Biology

Does protein aggregation drive postmitotic tissue degeneration?

Jeffery W. Kelly

Summary: Pharmacological evidence from clinical trials suggests that protein aggregation plays a key role in tissue degeneration in systemic amyloid diseases, with ongoing investigations focusing on the protein aggregate structures driving tissue pathology and the similarities in etiology between these diseases and Alzheimer's disease.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Review Chemistry, Medicinal

Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story

Arianna Burton, Adam Castano, Marianna Bruno, Steve Riley, Jennifer Schumacher, Marla B. Sultan, Sandi See Tai, Daniel P. Judge, Jignesh K. Patel, Jeffery W. Kelly

Summary: Rare diseases are considered a global public health priority, with Tafamidis representing a major breakthrough in the treatment of transthyretin amyloidosis after decades of research and clinical trials that established its safety and efficacy.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

Article Biochemistry & Molecular Biology

Metabolically Activated Proteostasis Regulators Protect against Glutamate Toxicity by Activating NRF2

Jessica D. Rosarda, Kelsey R. Baron, Kayla Nutsch, Gabriel M. Kline, Caroline Stanton, Jeffery W. Kelly, Michael J. Bollong, R. Luke Wiseman

Summary: Research has shown that the small molecule proteostasis regulator AA147 can protect against glutamate-induced cell death in neuronal-derived cell culture models. This protective effect is primarily mediated through the activation of the NRF2-regulated oxidative stress response, rather than the ATF6 pathway. These findings highlight the potential of metabolically activated proteostasis regulators like AA147 to activate both protective ATF6 and NRF2 signaling pathways to mitigate oxidative damage associated with various neurological diseases.

ACS CHEMICAL BIOLOGY (2021)

Article Biochemistry & Molecular Biology

Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation

Fabrizio Chiti, Jeffery W. Kelly

Summary: Protein misfolding diseases are caused by structural abnormalities in proteins, and specific small molecules have been approved to stabilize the folded state of these proteins, providing a promising approach to treat such diseases.

CURRENT OPINION IN STRUCTURAL BIOLOGY (2022)

Article Multidisciplinary Sciences

ATF6 is essential for human cone photoreceptor development

Heike Kroeger, Julia M. D. Grandjean, Wei-Chieh Jerry Chiang, Daphne D. Bindels, Rebecca Mastey, Jennifer Okalova, Amanda Nguyen, Evan T. Powers, Jeffery W. Kelly, Neil J. Grimsey, Michel Michaelides, Joseph Carroll, R. Luke Wiseman, Jonathan H. Lin

Summary: ER stress and UPR signaling contribute to human diseases, including severe congenital vision loss conditions like achromatopsia. Loss-of-function ATF6 variants lead to defective cone formation in the retina, highlighting the essential role of ATF6 in human cone development. Pharmacologic targeting of the ATF6 pathway may hold potential for treating blinding retinal diseases.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Chemistry, Medicinal

Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site

Nicholas L. Yan, Reji Nair, Alan Chu, Ian A. Wilson, Kristen A. Johnson, Gareth J. Morgan, Jeffery W. Kelly

Summary: This study investigates the potential of finding small molecule kinetic stabilizers in immunoglobulin light chain amyloidosis, identifying coumarin-based compounds with potential therapeutic effects. Structural-activity relationship data reveals that these compounds bind at different sites in the LC dimer, exerting unique stabilizing effects on LCs.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)

Review Biochemistry & Molecular Biology

Inverse Drug Discovery identifies weak electrophiles affording protein conjugates

Gabriel M. Kline, Karina Nugroho, Jeffery W. Kelly

Summary: In this review, we examine the application of Inverse Drug Discovery method using organic compounds of intermediate complexity harboring Sulfur(VI)-fluoride exchange (SuFEx) electrophiles to expand the cellular proteins that can be targeted covalently.

CURRENT OPINION IN CHEMICAL BIOLOGY (2022)

Article Biochemistry & Molecular Biology

Pharmacological activation of ATF6 remodels the proteostasis network to rescue pathogenic GABAA receptors

Meng Wang, Edmund Cotter, Ya-Juan Wang, Xu Fu, Angela L. Whittsette, Joseph W. Lynch, R. Luke Wiseman, Jeffery W. Kelly, Angelo Keramidas, Ting-Wei Mu

Summary: This study demonstrates that pharmacologically enhancing endoplasmic reticulum (ER) proteostasis can increase the assembly, trafficking, and surface expression of variant GABA(A) receptors, offering a potential opportunity to mitigate pathology associated with genetic epilepsy and other disease-associated variant ion channels.

CELL AND BIOSCIENCE (2022)

Article Cell Biology

ATF6 Activation Reduces Amyloidogenic Transthyretin Secretion through Increased Interactions with Endoplasmic Reticulum Proteostasis Factors

Jaleh S. Mesgarzadeh, Isabelle C. Romine, Ethan M. Smith-Cohen, Julia M. D. Grandjean, Jeffery W. Kelly, Joseph C. Genereux, R. Luke Wiseman

Summary: This study identified ER proteostasis factors involved in ATF6-dependent reductions in destabilized TTR secretion through a mass-spectrometry-based interactomics approach. Activation of ATF6 reduces the secretion and subsequent aggregation of amyloidogenic TTR through increased interactions with ATF6-regulated ER proteostasis factors including BiP and PDIA4. PDIA4 retains destabilized TTR in the ER through a redox-independent mechanism. These findings provide a mechanistic basis for the therapeutic targeting of ATF6 activation to improve treatments for TTR-related amyloid diseases.
Article Geriatrics & Gerontology

Analysis of lumbar spine stenosis specimens for identification of amyloid

Mathew S. Maurer, Dia Smiley, Eli Simsolo, Fabrizio Remotti, Angela Bustamante, Sergio Teruya, Stephen Helmke, Andrew J. Einstein, Ronald Lehman, Jon T. Giles, Jeffery W. Kelly, Felix Tsai, William S. Blaner, Pierre-Jacques Brun, Ron Riesenburger, James Kryzanski, Cindy Varga, Ayan R. Patel

Summary: Lumbar spinal stenosis (LSS) is a common reason for spine surgery in older adults, with amyloid detected in over one third of patients, especially in those over 75 years old. Age, clinical symptoms, cardiac biomarkers, and other parameters did not differ significantly between patients with and without amyloid.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2022)

Article Biochemistry & Molecular Biology

Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response

Cecilia Monteiro, Jaleh S. Mesgarzadeh, Joao Anselmo, Joana Fernandes, Marta Novais, Carla Rodrigues, David L. Powers, Evan T. Powers, Teresa Coelho, Jeffery W. Kelly

Summary: This study explored the relationship between TTR stabilization markers and clinical efficacy of tafamidis treatment. The results showed an increase in native TTR concentration and a decrease in non-native TTR concentration. However, changes in native and non-native TTR levels were not correlated with clinical response to tafamidis. Successful tafamidis therapy requires moderate TTR stabilization, and male patients may benefit from higher doses of tafamidis.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2023)

Article Biochemistry & Molecular Biology

Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange

Felix J. J. Tsai, Luke T. T. Nelson, Gabriel M. M. Kline, Marcus Jager, John L. L. Berk, Yoshiki Sekijima, Evan T. T. Powers, Jeffery W. Kelly

Summary: This study investigated the plasma concentrations of diflunisal and its efficacy in treating TTR polyneuropathy, finding that at a certain concentration, diflunisal can effectively slow down TTR dissociation rate and inhibit aggregation.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2023)

暂无数据